The U.S. Food and Drug Administration has granted Orphan Drug Designation to GT-GLA-S03, Glafabra Therapeutics’ lead cell therapy candidate for classic Fabry disease. This designation provides seven years of market exclusivity, approximately $4.68 million in fee exemptions, and tax credits, which the company states de-risks the development program and signals regulatory validation of their scientific approach.
GT-GLA-S03 represents a potential paradigm shift in treating Fabry disease, a lysosomal storage disorder. According to the company’s announcement, five years of clinical data demonstrate the therapy is safe, effective, and durable. The treatment could replace an estimated 130 clinic visits over five years with a single administration. A key feature is that the therapy is redosable when needed, addressing a significant limitation of many current treatments.
The therapy is built on Glafabra’s proprietary Live-cel™ platform. This same platform is already in preclinical development for two other lysosomal storage disorders: Pompe disease and Gaucher disease. These three conditions represent a combined patient population of approximately 2 million people who currently lack durable treatment options. The company’s pipeline includes GT-GAA-S04 for Pompe disease and GT-GBA1-S05 for Gaucher disease.
The Orphan Drug Designation follows five years of human clinical data supporting GT-GLA-S03 and the issuance of U.S. patent 12,540,336. Scientific references cited by the company include studies published in Clinical and Translational Medicine (2025) and Nature Communications (2021), along with clinical trial identifier NCT02800070. The company maintains its corporate website at https://www.glafabra.com.
It is important to note that Orphan Drug Designation does not indicate that GT-GLA-S03 is safe or effective for treating Fabry disease. The therapy remains investigational and is not approved by the FDA or any other regulatory authority. The clinical data referenced are from a pilot study. The announcement underscores a significant step toward developing a one-time, durable treatment for a rare disease that currently requires lifelong, frequent medical interventions.
This news story relied on content distributed by Reportable. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is FDA Grants Orphan Drug Designation to Glafabra’s Redosable Cell Therapy for Fabry Disease.